Glasdegibmaleate

Drug Overview

Glasdegib Maleate is a potent, small-molecule Targeted Therapy designed to treat specific forms of acute leukemia. Marketed under the brand name Daurismo™, it acts as a selective inhibitor of the Hedgehog signaling pathway, a critical biological mechanism that regulates cell growth and differentiation. By disrupting this pathway, glasdegib targets the self-renewal capacity of cancer cells, specifically addressing the root cause of leukemia progression and resistance.

• Generic Name: Glasdegib maleate
• US Brand Name: Daurismo™
• Drug Class: Hedgehog Pathway Inhibitor (Smoothened Antagonist)
• Route of Administration: Oral (Tablets)
• FDA Approval Status: Approved (First approved in 2018)

glasdegibmaleate is a strong defense for those fighting AML. Discover how this effective medication improves survival rates for seniors.

What Is It and How Does It Work? (Mechanism of Action)

Glasdegib maleate functions by inhibiting the Hedgehog (Hh) signaling pathway, which is normally active during embryonic development but becomes dormant in most adult tissues. In certain cancers, including Acute Myeloid Leukemia (AML), this pathway is reactivated, driving the survival and proliferation of leukemic stem cells.

Molecular Mechanism:

1. Pathway Activation: In the absence of a signal, the transmembrane receptor Patched (PTCH) inhibits another receptor called Smoothened (SMO). When Hedgehog ligands bind to PTCH, this inhibition is released, allowing SMO to become active.
2. SMO Inhibition: Glasdegib binds specifically to the Smoothened (SMO) protein. It acts as an antagonist, locking SMO in an inactive state even if Hedgehog ligands are glasdegibmaleate present.
3. GLI Transcription Blockade: By inhibiting SMO, glasdegib prevents the downstream activation and nuclear translocation of GLI transcription factors (GLI1, GLI2).
4. Stem Cell Exhaustion: GLI factors are responsible for turning on genes that promote cell survival and self-renewal. By blocking this signal, glasdegib reduces the population of dormant Leukemic Stem Cells (LSCs), sensitizing them to chemotherapy and preventing disease relapse.

FDA Approved Clinical Indications

Glasdegib is FDA-approved for the treatment of adult patients with specific hematologic malignancies.

Oncological Uses:

• Acute Myeloid Leukemia (AML): Indicated in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed AML in adult patients who are:
  •  75 years old, OR
  • Have comorbidities that preclude the use of intensive induction chemotherapy.

Non-Oncological Uses:

• There are currently no FDA-approved non-oncological indications for glasdegib.

Dosage and Administration Protocols

Glasdegib is supplied as 25 mg and 100 mg film-coated tablets.

Standard Dosing Regimen

Dose Adjustments:

• Renal Impairment: No dose adjustment is recommended for mild to severe renal impairment.
• Hepatic Impairment: No dose adjustment is recommended for glasdegibmaleate mild to moderate hepatic impairment. It has not been studied in severe hepatic impairment.
• QTc Prolongation: If QTc interval >500 ms, withhold treatment. Resume at a reduced dose (50 mg) once QTc returns to baseline or 480 ms.
• Concomitant CYP3A Inducers: Avoid strong CYP3A4 inducers. If moderate inducers cannot be avoided, increase glasdegib dose to 200 mg daily.

Clinical Efficacy and Research Results

The efficacy of glasdegib was established in the pivotal BRIGHT AML 1003 trial. Recent long-term follow-up data (2020–2024 analysis periods) continues to support its role in older, unfit populations.

• Overall Survival (OS): The combination of glasdegib + low-dose cytarabine (LDAC) demonstrated a significant survival benefit compared to LDAC alone.
  • Median OS: Approximately 8.3 months for the glasdegib arm versus 4.3 months for the LDAC alone arm.
  • Hazard Ratio: The risk of death was reduced by roughly 54% (HR 0.46) in the combination arm.
• Clinical Response: The Complete Response (CR) rate was significantly higher with glasdegib (approx. 17-19%) compared to LDAC alone (approx. 2%).
• Real-World Evidence (2023-2024): Observational studies indicate that glasdegib serves as a viable alternative for patients who are ineligible for Venetoclax-based regimens glasdegibmaleate (the current standard of care) due to drug interactions or toxicity profiles, maintaining its place in the AML treatment algorithm.

Safety Profile and Side Effects

BLACK BOX WARNING: EMBRYO-FETAL TOXICITY

Glasdegib can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential prior to initiating therapy,glasdegibmaleate. Advise females and males of reproductive potential to use effective contraception during treatment and for at least 30 days (females) or 4 months (males) after the last dose.

Common Side Effects (>20%)

• Hematologic: Anemia (low red blood cells), thrombocytopenia (low platelets), neutropenia (low white blood cells), febrile neutropenia.
• Constitutional: Fatigue, pyrexia (fever), edema (fluid retention).
• Gastrointestinal: Nausea, constipation, decreased appetite, dysgeusia (taste changes), mucositis.
• Musculoskeletal: Muscle spasms, pain in extremities.
• Respiratory: Dyspnea (shortness of breath), cough.

Serious Adverse Events

• QTc Prolongation: A heart rhythm disorder that can lead to serious arrhythmia. Occurs in ~5-8% of patients.
• Severe Cytopenias: Grade 3 or 4 reductions in blood cells leading to severe infection (pneumonia, sepsis) or hemorrhage.
• Muscle Spasms: Can be severe and impact daily function.

Management Strategies:

• QT Monitoring: Perform ECGs at baseline, then once weekly for the first month, and once monthly thereafter. Correct electrolyte imbalances (potassium, magnesium) immediately.
• Blood Counts: Monitor Complete Blood Counts (CBC) weekly for the first month, then at least monthly. Transfusions and antibiotics may be required.

Connection to Stem Cell and Regenerative Medicine

Glasdegib is a prime example of a therapy developed specifically based on Cancer Stem Cell (CSC) theory.

• Targeting Leukemic Stem Cells (LSCs): Unlike traditional chemotherapy, which targets rapidly dividing bulk tumor cells, glasdegib targets the dormant Leukemic Stem Cells. These stem cells often reside in the bone marrow niche and are resistant to standard chemotherapy.
• Regenerative Exhaustion: By inhibiting the Hedgehog pathway, glasdegib forces these quiescent stem cells to exit dormancy and differentiate or undergo apoptosis. This effectively exhausts the regenerative capacity of the leukemia, preventing the LSCs from regenerating the tumor after chemotherapy has cleared the bulk disease of glasdegibmaleate
• Relapse Prevention: This mechanism is crucial for preventing relapse, as surviving LSCs are the primary cause of cancer recurrence in AML.

Patient Management & Practical Recommendations

Pre-Treatment Tests

• Cardiac Evaluation: Baseline ECG to measure QTc interval.
• Electrolytes: Serum potassium, magnesium, and calcium (to minimize QT risk).
• Complete Blood Count (CBC): Baseline assessment.
• Pregnancy Test: Mandatory for females of reproductive potential.
• Creatine Kinase (CK): Often checked baseline due to risk of muscle spasms.

Precautions During Treatment

• Blood Donation: Patients must not donate blood or blood products during treatment and for at least 30 days after the last dose to prevent exposure to potential recipients (e.g., pregnant women).
• Semen Donation: Males must not donate semen during treatment and for at least 4 months after the last dose.

Do’s and Don’ts List

• DO use effective contraception. Males must use condoms even with vasectomy to protect female partners.
• DO report muscle cramps, leg swelling, or palpitations to your doctor immediately.
• DO maintain hydration and electrolyte balance to protect your heart rhythm.
• DON’T consume grapefruit or grapefruit juice, as it acts as a CYP3A inhibitor and can increase drug levels to toxic limits.
• DON’T stop taking the medication due to taste changes (dysgeusia) without consulting your oncologist; nutritional support is available.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is intended for international patients and healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Glasdegib maleate (Daurismo™) is a prescription medication; its use must be determined by a qualified oncologist based on individual patient history, cardiac status, and genetic profiling. Dosing, protocols, and approval status may vary by country and regulatory jurisdiction. Always consult with a healthcare provider regarding specific medical conditions and treatment options.